Jilani S M, Glaspy J A
Division of Hematology-Oncology, University of California, Los Angeles 90024-6956, USA.
Semin Oncol. 1998 Oct;25(5):571-6.
Anemia associated with cancer and cytotoxic chemotherapy contributes adversely to the quality of life (QOL) of these patients. RBC transfusions have been the traditional treatment, but due to the associated risks, they are not routinely used to treat mild and moderate degrees of anemia Therapy with recombinant human erythropoietin ([EPO] epoetin alfa) in these patients has been effective for both prevention and treatment of anemia, and in decreasing transfusion requirements. More importantly, studies have shown that the addition of epoetin alfa therapy to the treatment of patients receiving cancer chemotherapy is associated with a significant increase in energy level, functional status, and overall QOL. Further studies will be required to define the most efficient and cost-effective dose and schedule of epoetin alfa during cancer chemotherapy, so that its benefits will be available to as many patients as possible. The most important studies will be focused on defining the relationship of dose to response, identifying early predictors of response, and determining cost-effectiveness.
与癌症和细胞毒性化疗相关的贫血会对这些患者的生活质量（QOL）产生不利影响。红细胞输血一直是传统的治疗方法，但由于存在相关风险，它们并不常规用于治疗轻度和中度贫血。在这些患者中，使用重组人促红细胞生成素（[EPO] 阿法依泊汀）进行治疗对贫血的预防和治疗以及减少输血需求均有效。更重要的是，研究表明，在接受癌症化疗的患者治疗中添加阿法依泊汀疗法与能量水平、功能状态和总体生活质量的显著提高相关。需要进一步研究来确定癌症化疗期间阿法依泊汀最有效且具成本效益的剂量和给药方案，以便尽可能多的患者能够受益。最重要的研究将集中于确定剂量与反应的关系、识别反应的早期预测指标以及确定成本效益。
